Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR-T

Adam M Kase; Mohamed A Kharfan-Dabaja; Andrew Donaldson; Jamie Elliott; Taimur Sher

doi:10.1002/ccr3.5572

Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR-T

Clin Case Rep. 2022 Apr 8;10(4):e05572. doi: 10.1002/ccr3.5572. eCollection 2022 Apr.

Authors

Adam M Kase¹, Mohamed A Kharfan-Dabaja², Andrew Donaldson¹, Jamie Elliott¹, Taimur Sher¹

Affiliations

¹ Mayo Clinic Florida Division of Hematology Oncology Jacksonville Florida USA.
² Blood and Marrow Transplantation and Cellular Therapies Program Mayo Clinic Florida Division of Hematology Oncology Jacksonville Florida USA.

Abstract

Patients with relapsed follicular lymphoma who do not respond to CAR-T have a poor outcome. We present a case of refractory follicular lymphoma who relapsed after two CAR-T infusions and achieved a complete remission after treatment with obinutuzumab and lenalidomide. This represents a promising treatment option in the post-CAR-T setting.

Keywords: CAR‐T; follicular lymphoma; immunotherapy; lenalidomide; obinutuzumab.

Publication types

Case Reports